{"id":1205,"date":"2020-01-10T16:23:05","date_gmt":"2020-01-10T16:23:05","guid":{"rendered":"http:\/\/lightox.co.uk\/?page_id=1205"},"modified":"2023-03-27T10:07:32","modified_gmt":"2023-03-27T10:07:32","slug":"about","status":"publish","type":"page","link":"https:\/\/lightox.co.uk\/about\/","title":{"rendered":"About"},"content":{"rendered":"
[vc_row thb_full_width=”true” thb_row_padding=”true” thb_column_padding=”true” content_placement=”middle” parallax=”content-moving” parallax_image=”2766″ el_class=”align-center” css=”.vc_custom_1625478209258{padding-top: 25vh !important;padding-bottom: 10vh !important;background-color: #643cff !important;background-position: center;background-repeat: no-repeat !important;background-size: cover !important;}” el_id=”header”][vc_column offset=”vc_col-lg-11″][vc_row_inner content_placement=”middle”][vc_column_inner width=”2\/3″][vc_column_text animation=”animation bottom-to-top”]\n
\n
ABOUT \u00a0 <\/span>I\u00a0\u00a0 LIGHTOX<\/span>
\n<\/strong><\/h6>\n<\/div>\n[\/vc_column_text][vc_column_text css=”.vc_custom_1625562206839{padding-right: 6vw !important;}”]\n

LightOx has developed<\/span> new therapies for mouth cancers.<\/span><\/h1>\n[\/vc_column_text][vc_column_text animation=”animation bottom-to-top” css=”.vc_custom_1625489085241{padding-right: 5vw !important;}”]\n
Our drug retains efficacy in cancer cell targets and overall drug potency is increased greater than 10-fold after light treatment.<\/span><\/h5>\n[\/vc_column_text][vc_empty_space height=”6vh”]\t\n\t\tLEARN MORE<\/span>\n\t\t\t<\/a>\n\t\t[\/vc_column_inner][vc_column_inner width=”1\/3″ css=”.vc_custom_1625477737376{padding-right: 3vw !important;}”][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row thb_full_width=”true” thb_row_padding=”true” thb_column_padding=”true” el_class=”align-center” css=”.vc_custom_1625494843646{padding-top: 120px !important;background-color: #edf2f4 !important;}” el_id=”INTRO”][vc_column offset=”vc_col-lg-9 vc_col-md-8″][vc_row_inner][vc_column_inner el_class=”text-center”][vc_column_text animation=”animation bottom-to-top”]\n
Overview<\/span><\/h5>\n[\/vc_column_text][vc_column_text animation=”animation bottom-to-top”]\n

LightOx is developing its technology platform,<\/span> with our lead candidate LXD191 being developed for oral cancer treatments.<\/span><\/h2>\n[\/vc_column_text][vc_column_text animation=”animation bottom-to-top”]\n

Further applications are being developed in other clinical and non-clinical areas.<\/span>
\n<\/span><\/h4>\n[\/vc_column_text][vc_empty_space height=”5vh”][vc_column_text animation=”animation bottom-to-top”]\n

LightOx\u2019s ability to target cancers is a key aspect of our strategy.<\/strong><\/span><\/p>\n[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_empty_space height=”1vh”][vc_row_inner][vc_column_inner width=”1\/2″][vc_column_text animation=”animation bottom-to-top”]\n

\n

We are developing a portfolio of light activated cytotoxic therapeutics that have been formulated for use in the treatment of oral cancers via a topical delivery method. Our small molecule drugs act as selective therapeutics, where uptake and activity preferentially occurs in cancerous cells.<\/p>\n

These therapeutics are cytotoxic and can be linked to cell-specific targeting antibodies, peptides or nucleic acids (LightOx-ADCs) where required.<\/p>\n

LightOx has developed a new class of small molecule fluorescent drug-like compounds which overcome the limitations of current light-based treatments.<\/p>\n<\/div>\n[\/vc_column_text][\/vc_column_inner][vc_column_inner width=”1\/2″][vc_column_text animation=”animation bottom-to-top”]\n

\n

These compounds have intrinsic light activated cell killing properties and have the potential to revolutionise light-based therapeutic markets.<\/p>\n<\/div>\n[\/vc_column_text][vc_column_text animation=”animation bottom-to-top”]\n

\n
Our molecules can be<\/span><\/h6>\n<\/div>\n[\/vc_column_text][vc_column_text animation=”animation bottom-to-top”]\n
\n